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PHeart Rhythm Disorders
Comparison of Empiric to Physician-Tailored
rogramming of Implantable Cardioverter-Defibrillators
esults From the Prospective Randomized Multicenter EMPIRIC Trial
ruce L. Wilkoff, MD, FACC,* Kevin T. Ousdigian, MS,† Laurence D. Sterns, MD, FACC,‡
engri J. Wang, PHD,† Ryan D. Wilson, MBA,† John M. Morgan, MD, FACC,§
or the EMPIRIC Trial Investigators
leveland, Ohio; Minneapolis, Minnesota; Victoria, British Columbia, Canada; and Southampton, England
OBJECTIVES The purpose of this randomized study was to determine whether a strategically chosen
standardized set of programmable settings is at least as effective as physician-tailored choices, as
measured by the shock-related morbidity of implantable cardioverter-defibrillator (ICD) therapy.
BACKGROUND Programming of ventricular tachyarrhythmia (ventricular tachycardia [VT] or ventricular
fibrillation [VF]) detection and therapy for ICDs is complex, requires many choices by highly
trained physicians, and directly influences the frequency of shocks and patient morbidity.
METHODS A total of 900 ICD patients were randomly assigned to standardized (EMPIRIC, n  445)
or physician-tailored (TAILORED, n 455) VT/VF programming and followed for 1 year.
RESULTS The primary end point was met: the adjusted percentages of both VT/VF (22.3% vs. 28.7%)
and supraventricular tachycardia or other non-VT/VF event episodes (11.9% vs. 26.1%) that
resulted in a shock were non-inferior and lower in the EMPIRIC arm compared to the
TAILORED arm. The time to first all-cause shock was non-inferior in the EMPIRIC arm
(hazard ratio  0.95, 90% confidence interval 0.74 to 1.23, non-inferiority p  0.0016). The
EMPIRIC trial had a significant reduction of patients with 5 or more shocks for all-cause
(3.8% vs. 7.0%, p  0.039) and true VT/VF (0.9% vs. 3.3%, p  0.018). There were no
significant differences in total mortality, syncope, emergency room visits, or unscheduled
outpatient visits. Unscheduled hospitalizations occurred significantly less often (p 0.001) in
the EMPIRIC arm.
CONCLUSIONS Standardized empiric ICD programming for VT/VF settings is at least as effective as
patient-specific, physician-tailored programming, as measured by many clinical outcomes.
Simplified and pre-specified ICD programming is possible without an increase in shock-
related morbidity. (J Am Coll Cardiol 2006;48:330–9) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.03.037Cardiology Foundation
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2he Center for Medicaid and Medicare Services recently
ublished expanded coverage for implantable cardioverter-
efibrillator (ICD) therapy based on the mortality benefit
emonstrated in the SCD-HeFT (Sudden Cardiac Death
n Heart Failure Trial), DEFINITE (Defibrillators in
onischemic Cardiomyopathy Treatment Evaluation) trial,
he MADIT-II (Multicenter Automatic Defibrillator Im-
lantation Trial-II), and the COMPANION (Comparison
f Medical Therapy, Resynchronization, and Defibrillation
herapies in Heart Failure) trial (1–5). However, ICDs can
e associated with patient morbidity and worse quality of
ife when the patient receives painful shocks, especially
ultiple shocks (6–9). With expanded indications for ICD
mplantation, concern has developed about who should
mplant, program, and follow these devices and what kind of
raining is required for these individuals (10–13). More
From *The Cleveland Clinic Foundation, Cleveland, Ohio; †Medtronic, Inc.,
inneapolis, Minnesota; ‡Victoria Cardiac Arrhythmia Trials, Victoria, British
olumbia, Canada; and §Wessex Cardiology, Southampton, England. This study
as supported by a grant from Medtronic, Inc.p
Manuscript received October 24, 2005; revised manuscript received March 7, 2006,
ccepted March 28, 2006.mportantly, how can consistent expert care be delivered to
very patient in order for them to receive the benefits of
CDs without substantial morbidity?
Implantable cardioverter-defibrillator therapy can involve
any complex choices, including more than 100 programma-
le parameter values that determine the detection and treat-
ent of rhythms presented to the device. There are multiple
rogramming strategies for reducing the number of morbid
vents related to shocks. Some publications have suggested that
ntitachycardia pacing (ATP) is not needed for patients with-
ut a prior history of a clinical tachycardia (2,10), whereas
thers have suggested that more than 70% of ventricular
achyarrhythmias can be terminated safely without a shock if
TP is given a chance (7,14,15). It has been assumed that
atient-specific customization of all these parameters is crucial
o the ICD’s appropriate response, so that all life-threatening
rrhythmias are treated with minimal shocks delivered to the
atient for non–life-threatening arrhythmias. This assumption
s based on two premises: 1) the physician programming the
CD knows which strategies will produce the best results, and
) a patient-specific customization of the programming will
roduce the best protection with the least morbidity.
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July 18, 2006:330–9 Empiric Versus Physician-Tailored Programming of ICDsThis investigation tests the hypothesis that, as measured
y shock-related morbidity, an initial programming strategy
sing a well-constructed set of tachyarrhythmia detection
nd therapy parameters (EMPIRIC parameters), when
onsistently applied to a large group of unselected ICD
atients, would be as successful as an individualized patient-
pecific, physician-tailored (TAILORED) set of parame-
ers. The hypothesis requires that the EMPIRIC parame-
ers perform as well as the control group in two ways: 1)
ercentage of ventricular arrhythmias that are shocked, and
) percentage of supraventricular tachycardia or other non-
entricular tachycardia (VT)/ventricular fibrillation (VF)
vents (SVTs) that are shocked.
ETHODS
he EMPIRIC (Comparison of Empiric to Physician-
ailored Programming of Implantable Cardioverter-
efibrillators) trial was a worldwide, multicenter, single-
lind, non-inferiority, parallel-group, 1:1 randomized trial
f ICD programming (16). Enrollment was conducted at 54
enters in the U.S., Canada, Europe, and the Middle East
etween August 2002 and October 2003. The institutional
eview board at each center approved the study protocol, and
ritten informed consent was obtained from each patient.
ARTICIPANTS AND ICD PLACEMENT
ll patients had standard indications for ICD placement as
efined by the American College of Cardiology/American
eart Association/North American Society for Pacing and
Table 1. EMPIRIC Arm Programming of VT
Detection Threshold De
VF on 250 beats/min
FVT via VF 200 beats/min (
VT on 150 beats/min
Supraventricular tachycardia criteria on: atrial fibrillation/atri
Abbreviations and Acronyms
AF  atrial fibrillation
AFL  atrial flutter
AT  atrial tachycardia
ATP  antitachycardia pacing
CI  confidence interval
EMPIRIC  Comparison of Empiric to Physician-
Tailored Programming of Implantable
Cardioverter-Defibrillators trial
GEE  general estimating equation
HR  hazard ratio
ICD  implantable cardioverter-defibrillator
RR  relative risk
SVT  supraventricular tachycardia or other
non-VT/VF event
VF  ventricular fibrillation
VT  ventricular tachycardia200 beats/min. Burst ATP: 8 intervals, R-S1 88%, 20 ms decreme
ATP  antitachycardia pacing; FVT  fast ventricular tachycardilectrophysiology guidelines (17). Patients were considered
o have a secondary prevention indication for ICD place-
ent if there was a history of spontaneous sustained VT/VF
r syncope with suspected VT. All other patients were
onsidered to have a primary prevention indication. Patients
ad to be undergoing their first placement of an ICD and be
ree of permanent atrial fibrillation (AF).
All patients received a Model 7274 Marquis DR ICD
Medtronic Inc., Minneapolis, Minnesota) and were ran-
omized after successful implantation testing of the atrial
nd ventricular leads for sensing, capture, VF detection, and
efibrillation with a 10-J safety margin.
ANDOMIZATION
atients were randomized to have the tachyarrhythmia
etection and therapy programmed to prescribed values
EMPIRIC) or to values determined by the treating physi-
ian (TAILORED). The patients were blinded to the
andomization.
Randomization was done at the data-coordinating center
nd was stratified by the treatment center. The randomiza-
ion was based on permuted blocks with a block size of 2
nitially, followed by a block size of 2 or 4 with a probability
f 0.5 each. Since the incidence and prevalence of sponta-
eous VT/VF and SVT may be different between primary
revention patients, randomization was also stratified by
CD indication (secondary vs. primary).
ROGRAMMING
achyarrhythmia detection and therapy settings were stra-
egically chosen in the EMPIRIC arm to reduce shocks
or VT/VF and SVTs and to avoid untreated slow VT
Table 1). The key strategies included: 1) avoid detecting
on-sustained tachycardias;, 2) avoid detecting SVTs as VT;
) empirical ATP for slow and fast VTs; and 4) high-output
rst shocks. A more detailed discussion of these strategies is
ound in a paper outlining the rationale for the study design
16). The VT/VF programming was set at the discretion of
he implanting electrophysiologist in the TAILORED arm.
ll implanters and centers invited to participate had long-
stablished ICD placement and programming practices. In
rder to provide similar data collection in both arms, the VT
one was programmed to monitor rhythms faster than 150
eats/min in the TAILORED arm if the investigator chose
o have VT therapies off. Bradycardia settings were pro-
rammed at the discretion of the investigators in both arms.
Settings
eats Therapies
24 30 J  6
24) Burst (1 sequence), 30 J  5
Burst (2), ramp (1), 20 J, 30 J  3
er, sinus tach (1:1 VT-ST boundary  66%), SVT limit /VF
tect B
18 of
18 of
16
al flutt
nt. Ramp ATP: 8 intervals, R-S1 81%, 10 ms decrement.
a; VF  ventricular fibrillation; VT  ventricular tachycardia.
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Empiric Versus Physician-Tailored Programming of ICDs July 18, 2006:330–9rogramming changes during follow-up were allowed if
edically justified.
ATA COLLECTION
atients were followed for 12 months, with device interro-
ations and clinical evaluations at 3, 6, and 12 months. Data
ollection included VT/VF and SVT episodes, device pro-
ramming, medical justifications for VT/VF programming
hanges, cardiovascular medication, adverse device events,
- and R-wave measurements, and cardiovascular-related
ospitalizations. The VT/VF and SVT recorded events
ere classified by the electrophysiologist investigator and
hen blindly adjudicated by another expert. Episodes with-
ut agreement were further reviewed by study key-
nvestigator electrophysiologists for final classification.
inety-one percent (2,753 of 3,031) of final classifications
ere concordant with the initial classification.
ND POINTS
he percentage of recorded episodes in a therapeutic zone
hat produced a device shock for episodes determined to be
T/VF and those determined not to be VT/VF (i.e., SVT
r ventricular oversensing) were calculated separately. The
rimary end point requires that both distinct measurements
f efficacy not be inferior when comparing EMPIRIC to
AILORED programming. To make sure that the primary
nd point was not achieved at the expense of safety or
ealth-care utilization, death, syncope, hospitalization,
mergency room visits, and unscheduled outpatient visit
requency were recorded for analysis.
Planned and pre-defined secondary end points include
ime to first shock for all rhythms (VT/VF and SVT), only
T/VF rhythms, and only SVT rhythms. Additional pre-
efined analyses include evaluating the time-to-first-shock
nd points as a function of baseline characteristics and the
rogrammed parameters.
TATISTICAL ANALYSIS
he primary study outcome was evaluated according to the
ntent-to-treat principle. A per-protocol analysis was also
arried out, in which 830 patients without any major
rotocol deviations were included. The EMPIRIC pro-
ramming was considered non-inferior to the TAILORED
rogramming approach if both the percentage of shocked
T/VF episodes and the percentage of shocked SVT
pisodes were no more than 10 percentage points greater in
he EMPIRIC arm than the TAILORED arm. The chosen
argin of 10% was pre-specified to represent a threshold
hat is considered clinically relevant.
The sample size was determined on the basis of previous
rial data. It was assumed that during the 12-month
ollow-up period, 24% of patients would have at least one
rue VT/VF episode and 33% of patients would have at least
ne true SVT episode. The within-patient correlation
d
Aoefficient for multiple episodes was assumed to be 0.3.
ith a shock rate of 30% for VT/VF and 14% for SVT
pisodes, a total of 900 patients (450 in each arm) would
ive at least 80% power for the VT/VF hypothesis and 90%
ower for the SVT hypothesis, each tested at a one-sided
ignificance level of 0.05.
The percentage of shocked episodes was evaluated under
logistic regression model and the generalized estimating
quations (GEE) method, with an exchangeable working
orrelation structure to account for within-patient correla-
ion for multiple episodes (18). The confidence interval (CI)
or the percentage difference between the two study arms
as constructed using the bias-corrected accelerated boot-
trap method (19). All statistical analyses were performed
sing SAS (Version 9.1, SAS Institute Inc., Cary, North
arolina) and S-Plus (Version 6.2, Insightful Corp., Seattle,
ashington).
The EMPIRIC programming is considered to be non-
nferior to the TAILORED for the key secondary end
oint, time to first all-cause shock, if the upper confidence
imit for the hazard ratio (HR) is 1.5 (pre-defined in the
esign paper) (16).
ESULTS
atient demographics. A total of 900 patients were en-
olled and randomized in the trial. The baseline character-
stics (Table 2) of the patients are reflective of the mixture
able 2. Baseline Patient Characteristics
EMPIRIC
(n  445)
TAILORED
(n  455)
ge, yrs, mean (SD) 65.1 (12.4) 64.8 (12.7)
ale gender, % 82.7 79.8
VEF, %, mean (SD) 31.9 (13.1) 32.1 (12.3)
yocardial infarction 71.2 67.7
ypertension 57.5 49.5
eart failure 62.0 60.7
NYHA functional class I–II 47.2 46.4
NYHA functional class III–IV 14.8 14.3
yncope 31.9 33.6
istory of AF/AFL/AT 24.7 26.4
ey cardiac medications, %
Amiodarone 20.4 21.1
Beta-blocker 72.6 73.8
ndication for ICD, %
Secondary prevention 51.7 55.8
Spontaneous sustained
monomorphic VT
26.7 25.7
Spontaneous sustained VF 10.6 13.0
Syncope 14.4 17.1
Primary prevention 48.3 44.2
CAD, LVEF 40%, EP study  23.8 22.2
CAD, LVEF 40%, EP study 
or not done
17.5 16.0
Other primary prevention 7.0 5.9
ll baseline patient characteristics were similar except for hypertension (p  0.016).
AF  atrial fibrillation; AFL  atrial flutter; AT  atrial tachycardia; CAD 
oronary artery disease; EP  electrophysiology; ICD  implantable cardioverter-
efibrillator; LVEF  left ventricular ejection fraction; NYHA  New York Heart
ssociation; other abbreviations as in Table 1.
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July 18, 2006:330–9 Empiric Versus Physician-Tailored Programming of ICDsf patients with (n  484) and without (n  416) a prior
ocumented spontaneous VT/VF or syncope with suspected
T. The mean age of the patients was 65.0  12.6 years
ith mean left ventricular ejection fraction of 32.0  12.7.
xcept for hypertension (p  0.016), the baseline charac-
eristics of the two groups were similar.
rogramming demographics. There were 100 physicians
rom 51 centers that programmed the 455 patients in the
AILORED arm. There were substantial differences in the
igure 1. Programmed implantable cardioverter-defibrillator (ICD) th
ntitachycardia pacing (ATP) and/or shock therapy (number of patients w
rm). The dotted line illustrates that nearly all EMPIRIC arm patients ha
ailored programming was enabled to treat slower tachycardias in a much sm
n (number of patients with ATP on at each heart rate/number of patient
able 3. Baseline ICD Detection and Therapy Programming
etection and discrimination
Treated rate threshold‡, median, beats/min (n)
All patients
Patients with a history of spontaneous sustained monomorphic VT
All other patients
o. of beats to detect VF, % (n)
12 of 16
18 of 24
24 of 32
R logic turned on, % (n)
AF/AFL
Sinus tachycardia
1:1 VT-ST boundary§, % (n)
50%
66%
tability on, % (n)
igh rate timeout, % (n)
herapy
At least 1 ATP attempt for ventricular rates§, %, (n)
Faster than 200 beats/min
177–200 beats/min
Slower than 177 beats/min
1st VF therapy % (n)
20 J
20–26 J
28–30 J
One patient never returned programming information and one patient was discharg
he Wilcoxon rank sum test, as appropriate. ‡Treated rate threshold is the VT thresh
ertinent patients are included in the calculations.
Abbreviations as in Tables 1 and 2.hat nearly all EMPIRIC arm patients had ATP on up to 250 beats/min. In ma
aster heart rates.aseline programmed parameters for tachyarrhythmia detec-
ion and therapy between the two patient groups (Table 3)
Fig. 1). One of the most important differences is that the
MPIRIC arm devices were more frequently set to detect
nd treat slower tachycardias. Therefore, the patients en-
olled in that study arm would be more likely to have their
oderate-to-slow VTs and SVTs detected and treated by
he ICD. The EMPIRIC arm also had a higher number of
eats to detect VF, made greater and more sophisticated use
s versus heart rate. (A) Percentage of all patients programmed to
TP or shock therapy on at each heart rate/total number of patients in the
ir ICD enabled to treat tachycardias 150 beats/min. In marked contrast,
roportion of patients. (B) Percent of treated patients programmed to ATP
ATP or shock therapy on at each heart rate). The dotted line illustrates
EMPIRIC*
(n  445)
TAILORED
(n  455) p Value†
150 (443) 171 (455) 0.001
150 (119) 162 (117) 0.001
150 (324) 176 (338) 0.001
0.001
6% (27) 50% (228)
94% (416) 49% (225)
0% (0) 0.4% (2)
100% (442) 77% (350) 0.001
100% (442) 76% (348) 0.001
0.001
2% (10) 82% (287)
98% (432) 18% (61%)
0% (0) 2% (11)
0% (0) 0.2% (1)
99% (437) 25% (114) 0.001
99% (439) 70% (294) 0.001
100% (436) 95% (250) 0.001
0.001
1% (5) 15% (70)
3% (12) 29% (130)
96% (426) 56% (255)
h the ICD turned off. †p values were calculated using either the Fisher exact test or
en VT detection and therapy are turned on; otherwise, it is the VF threshold. §Onlyerapie
ith A
d the
aller p
s withed wit
old whrked contrast, a small proportion of tailored arm patients had ATP on at
o
a
h
p
f
p
h
V
s
T
e
b
E
T
T
c
n
E
1
e
o
T
T
E
l
e
P
S
t
(
f
a
u
p
p
(
f
a
s
c
t
e
m
T
fi
c
d
1
f
t
(
T
F
o
r
F
b
334 Wilkoff et al. JACC Vol. 48, No. 2, 2006
Empiric Versus Physician-Tailored Programming of ICDs July 18, 2006:330–9f the supraventricular tachycardia detection/discrimination
lgorithms, used more ATP therapy, and programmed a
igher VF first-shock energy. The percentage of all patients
rogrammed for treatment with ATP and/or shocks as a
unction of heart rate is shown in Figure 1, as is the
ercentage of these patients programmed with ATP at each
eart rate. The percentage of follow-up visits with any
T/VF detection or therapy programming change was
ignificantly lower in the EMPIRIC arm compared to the
AILORED arm (13.1% vs. 20.2%, p  0.0001). At the
nd of the follow-up, the rate threshold for treatment had
een made faster than baseline programming in more
MPIRIC arm patients (5.4% vs. 2.2%) and slower in more
AILORED arm patients (4.1% vs. 8.2%).
achycardia and shocks. The detected and shocked tachy-
ardia events are summarized in Figure 2. Overall, a similar
umber of patients received at least one shock in the
MPIRIC and TAILORED arms of the trial (18.2% vs.
9.1%). Although a similar number of true VT/VF
pisodes was detected in the two groups, there were more
f these episodes that were treated by an ICD shock in the
AILORED arm of the study (169 vs. 110, p  0.20).
here were significantly more SVT episodes detected in the
MPIRIC arm (1,083 vs. 585, p  0.001), but there was
ittle difference in the number of inappropriate shock
pisodes (125 vs. 118).
igure 2. Number of episodes by arm. (A) True ventricular tachycardia/ven
ther non-VT/VF event (SVT) episodes. Solid bars  shocked; ruled bar
ecurrences per patient.igure 3. Percentage of episodes shocked—primary end point in the trial. The u
ound. SVT  supraventricular tachycardia; other abbreviations as in Figure 2.rimary end point. The percentages of both VT/VF and
VT episodes that resulted in a shock were non-inferior in
he EMPIRIC arm in comparison to the TAILORED arm
Fig. 3). The GEE-adjusted VT/VF percentage was 22.3%
or the EMPIRIC arm and 28.7% for the TAILORED
rm, and the difference was 6.4% with a one-sided 95%
pper confidence boundary of 2.3%, which was less than the
re-specified non-inferiority margin of 10%. For SVTs, the
ercentages were more favorable for the EMPIRIC arm
11.9% vs. 26.1%, one-sided 95% upper confidence bound
or the difference 5.0%). Results of the per-protocol
nalysis were consistent with the percentages of episodes
hocked observed in the intent-to-treat analysis. Despite
onsiderably more detected events in the EMPIRIC arm,
here were numerically fewer shocked episodes and no
vidence for an inferior outcome with EMPIRIC program-
ing of VT/VF detection and therapy.
ime-to-first-shock secondary end points. The time to
rst all-cause shock was non-inferior in the EMPIRIC arm
ompared to the TAILORED arm based on the pre-
efined threshold (Fig. 4A) (HR  0.95, 90% CI 0.74 to
.23, non-inferiority p  0.0016) (16). Throughout the
ollow-up period, there was a modest trend toward a longer
ime to first VT/VF shock in the EMPIRIC arm (Fig. 4B)
HR  0.80, 90% CI 0.56 to 1.14, superiority p  0.297).
he time-to-first-SVT shock curves were similar during the
lar fibrillation (VT/VF) episodes. (B) True supraventricular tachycardia or
ot shocked. GEE  general estimating equation adjustment for multipletricu
s  npper bound for the percentage difference is 1-sided 95% upper confidence
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July 18, 2006:330–9 Empiric Versus Physician-Tailored Programming of ICDsrst 3 months of follow-up, and then there was a trend of
ore EMPIRIC arm patients receiving SVT shocks in the
ime period of about 3 to 6 months after implant. Toward
he end of the 1 year of follow-up, the time-to-first-SVT
hock curves were converging, and therefore there was no
tatistical difference in the time to first SVT shock (Fig. 4C)
HR  1.19, 90% CI 0.84 to 1.69).
afety and health-care utilization end points. Several
afety and health-care utilization end points are shown in
igure 5. The overall mortality rate (24 of 445 vs. 30 of 455;
R  0.80, 95% CI 0.47 to 1.38) was consistent with the
ates seen in the recently published ICD trials and was
igure 4. Time to first shock. (A) All-cause; (B) true VT/VF; (C) true
VT. CI  confidence interval; HR  hazard ratio; other abbreviations as
n Figures 2 and 3.on-inferior in the EMPIRIC arm of the trial (2–4). In tddition, the syncopal rates were low and similar. There
ere few adverse events for untreated slower VT (0 for
MPIRIC vs. 2 for TAILORED). There were also 29
rue VT episodes detected in the monitor zone of 16
AILORED arm patients. There was no difference in emer-
ency room visits (44 vs. 46; relative risk [RR] 0.98, 95% CI
.66 to 1.45) or unscheduled outpatient visits (308 vs. 293;
R  1.07, 95% CI 0.98 to 1.18); however, the EMPIRIC
rm had significantly fewer unscheduled hospitalizations (163
s. 216; RR  0.77, 95% CI 0.66 to 0.90, p  0.001).
ubgroup analysis. A subgroup analysis of time to first
hock was carried out with respect to main ICD indication,
jection fraction, baseline New York Heart Association
unctional class, amiodarone or sotalol, beta-blocker, and a
istory of inducible sustained VT/VF (electrophysiology
tudy), coronary artery disease, and AF/atrial flutter (AFL)/
trial tachycardia (AT) (Fig. 6). There were no significant
ifferences in any of these covariates; however, there was
modest trend toward a shorter time to first shock in
MPIRIC arm patients with a history of AF/AFL/AT
HR  1.62, 95% CI 0.94 to 2.87, p  0.082).
dditional shock and ATP analyses. Several other im-
ortant metrics for evaluating programming effects on
linical outcomes are shown in Table 4. The EMPIRIC
rogramming resulted in a statistically significant reduction
n the percentage of patients with at least 5 all-cause shocks
3.8% vs. 7.0%, p  0.039) and also those with at least 5
hocks for only true VT/VF (0.9% vs. 3.3%, p  0.018).
here was no significant difference in patients with at least 5
hocks for SVTs (2.5% vs. 3.5%, p  0.44). Interestingly, the
.4% (n 49 of 900) of patients with at least 5 all-cause shocks
ccounted for 73.1% (EMPIRIC 32.0%, TAILORED 41.1%)
f all shocks in the study.
The effect of ATP programming on shocks can be
valuated by examining only true monomorphic VT
pisodes that were treated with ATP or a shock. The
reated monomorphic VT episodes accounted for 83.4%
f all true VT/VF episodes (n  1,363). The EMPIRIC
rogramming approach of consistent and extensive ATP
esulted in a significantly higher proportion of monomor-
hic VT episodes treated with ATP (94.8% vs. 87.9%, p
0.001). This broader ATP application in the
MPIRIC arm resulted in a significant reduction in the
roportion of treated monomorphic VT episodes that
ere shocked (12.7% vs. 21.1%, p  0.001). The overall
TP efficacy was similar between the two arms (92.1%
s. 89.8%, p  0.23). The ATP efficacy was higher
90%) in both arms at heart rates of 200 beats/min or
lower. This was presumably due to the programming of
ultiple ATP sequences to treat VT at these rates. At
aster VT rates it was typical for only one ATP sequence
o be programmed and delivered, thus reducing ATP
fficacy to only about 75% in both arms. The EMPIRIC
TP programming trended towards a reduction in the
roportion of VT/VF episodes that were accelerated by
he initial ATP attempt; however, it was not significant
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.11).
ISCUSSION
s the indications for ICD placement expand, the aspect of
CD therapy most variable and unpredictable in its appli-
ation is the choice of the programmed settings. An
nacceptable result of the enlarged population of patients
ith ICDs and the expanded cohort of implanters is poorer
utcomes. The question is how to deliver ICD care with the
recision of the accumulated wisdom of the electrophysiol-
gy community. Certainly this is a concern of the Centers
or Medicare and Medicaid Services. The recent call for a
ational registry for primary prevention ICD patients asso-
iated with expanded coverage was partially motivated by a
esire to assure that the outcomes demonstrated within the
Figure 5. Safety and health-care utilization end points. ERigure 6. Subgroup analysis on time to first all-cause shock. AF atrial fibrillati
isease; EF  ejection fraction; EPS  electrophysiologic study; MVT  monomlinical trials can be replicated in generalized practice. The
MPIRIC trial results demonstrate that consistent strate-
ies and an initial dramatic simplification of the pro-
rammed selections produce at least equivalent clinical
utcomes to the individualized current standard of care.
TP. This trial was not designed to make unequivocal
onclusions about specific programming options. However,
here were significant differences in baseline programming
hat appear to be associated with the outcome differences.
irst, ATP was programmed more consistently and exten-
ively in the EMPIRIC arm. This EMPIRIC ATP pro-
ramming strategy resulted in the significantly higher pro-
ortion of monomorphic VT episodes that were treated
ith ATP in the EMPIRIC arm. The consistent ATP
pplication coupled with the high efficacy (92.1%) of ATP
or spontaneous VT led to a significant reduction in the
ergency room; other abbreviations as in Figures 2 and 4.on; AFL atrial flutter; AT atrial tachycardia; CAD coronary artery
orphic ventricular tachycardia; other abbreviations as in Figures 1 and 4.
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AILORED arm (p  0.001). This EMPIRIC ATP
trategy also appears to be one of the factors that resulted
n a significant reduction in the percentage of patients with
t least 5 all-cause or VT/VF shocks. This aspect of
MPIRIC programming may be the most clinically impor-
ant because several studies have demonstrated that patients
ho receive 5 or more shocks have a worse quality of life
8,9). The potential drawbacks to delivering ATP include
ccelerations and syncope, but neither was an issue, as only
.4% of the episodes were accelerated in the EMPIRIC arm
s. 7.8% in the TAILORED arm. There were no adverse
vent reports of syncope correlated with VT/VF in the
MPIRIC arm. These data and those of several other
tudies strongly suggest that ATP is an important aspect of
CD therapy because the majority of true VT/VF rhythms
hat are detected can be pace-terminated (7,14,15,20–22).
he prior reports also demonstrated that empirically pro-
rammed ATP is highly effective in painlessly terminating
Ts and confirm the safety of ATP therapy (e.g., low
cceleration rate, no increase in syncope). Therefore, em-
irical ATP should be used in virtually all ICD patients.
Second, systematic use of a VT zone with aggressive SVT
iscriminators in the EMPIRIC arm likely led to the
ignificant reduction in the percentage of true SVT episodes
hat were shocked (11.9% vs. 26.1%). This is consistent with
ndings by several others that have demonstrated dual-
hamber SVT discriminators reduce inappropriate detec-
ions versus rate-only detection (23–25). The quantity of
VTs seen by the ICD in the EMPIRIC arm was nearly 2
imes that in the TAILORED arm because the median
reated rate threshold was significantly slower (150 vs. 171
eats/min, p  0.001). It appears the EMPIRIC SVT
iscrimination approach was effective at reducing the per-
entage of SVT episodes shocked; however, the quantity of
VTs was so high at slower heart rates that this reduction
id not translate into a reduction in the time to first SVT
hock.
It is not clear that the choices employed in the EMPIRIC
rm are the best or should be the ultimate choices, but it
able 4. Additional Shock and ATP End-Points
ercentage of patients with 5 shocks (n patients)
All-cause
Only true VT/VF
Only true SVT
reated monomorphic VT episodes
Proportion treated with ATP
Proportion shocked
TP efficacy for monomorphic VTs
Ventricular rate 200 beats/min
Ventricular rate 200 beats/min
roportion of true VT/VF episodes accelerated by initial ATP attempt (%
bbreviations as in Tables 1 and 2.s clear that TAILORED programming is not always metter. The strategies that performed well suggest that
xtensive ATP and use of the SVT discrimination algo-
ithms were simple answers to a complex physiologic situ-
tion and were clinically beneficial. The initial strategy may
eed to be modified in a small minority of patients as their
esponse is observed. All patients in the EMPIRIC arm had
T detection and therapy enabled for rhythms faster than
50 beats/min. Particularly as an increased percentage of
CDs are implanted in patients without a history of sus-
ained slower VTs, raising the detection rate threshold for
his large set of patients seems to be a sensible strategy to
educe shocks for SVTs and has been suggested and/or
tudied by others (2, 26–29). Even with the slower detec-
ion rate threshold in the EMPIRIC arm, there was no
ignificant shock penalty paid for the dramatic increase in
VT episodes detected in the EMPIRIC arm of the trial
elative to the TAILORED arm. The faster detection rate
hreshold in the TAILORED arm may have resulted in
ore untreated VTs, which may at times cause significant
ymptoms (30).
Implantable cardioverter-defibrillator morbidity due to
hocks and the potential for shocks demand that we reduce
he number and frequency of both appropriate and inap-
ropriate shocks. This trial demonstrated that many shocks
hat would have been considered appropriate (e.g., mono-
orphic VT shocks) were in fact avoidable and thus could
e considered unnecessary, since ATP could have prevented
he shocks. In addition, most supraventricular tachycardia
pisodes overlapping with ICD therapy zones can be ap-
ropriately classified and not treated with ICD shocks.
lthough the mortality benefit conferred by ICD therapy in
ndicated populations is a critical yardstick of the therapy’s
fficacy, it is vital to remember that shock-related morbidity
s the critical yardstick of the therapy’s iatrogenic morbidity.
dvances in ICD therapy must continue to focus on
educing both shock therapies for termination of life-
hreatening VT/VF and shock therapies delivered in re-
ponse to non–life-threatening arrhythmias. There is no
alue in customizing the programming of the ICD if it does
ot improve the patient outcomes. Alternatively, there is
EMPIRIC
(n  445)
TAILORED
(n  455) p Value
3.8% (17) 7.0% (32) 0.039
0.9% (4) 3.3% (15) 0.018
2.5% (11) 3.5% (16) 0.44
534 602
94.8% (506/534) 87.9% (529/602) 0.001
12.7% (68/534) 21.1% (127/602) 0.001
92.1% (466/506) 89.8% (475/529) 0.23
93.9% (431/459) 90.9% (448/493) 0.088
74.5% (35/47) 75.0% (27/36) 1.0
ents) 2.4% (2.0%) 7.8% (3.1%) 0.11patiuch value in simplification of the programming strategy,
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Empiric Versus Physician-Tailored Programming of ICDs July 18, 2006:330–9specially if, as suggested in this trial, the shock morbidity is
aintained or reduced and there is no difference in mortal-
ty, syncope, or health-care utilization.
tudy limitations. The shock metrics used in this trial
ere chosen for various reasons described in the design
aper; however, there are multiple ways of assessing the
hock morbidity of ICDs (16). Every attempt was made to
rovide an unbiased analysis, but because of detection rate
ettings, limitations in device memory that provide incom-
lete electrogram records, use of only dual-chamber devices,
nd the need to test a specific set of EMPIRIC parameters,
hese data provide only partial insight into these program-
ing choices. Patient syncope diaries may have provided
ore complete documentation of syncopal events; however,
ecent trials have suggested very low syncope rates (7). In
ddition, this trial was designed only to test the empiric
rogramming approach as the initial strategy for program-
ing after implantation. Programming changes were
eeded in both arms during follow-up. Finally, the same
MPIRIC parameters were applied to all patients regard-
ess of the clinical presentation for the implantable defibril-
ator. The indications for ICDs are evolving, and the
ptimal set of empiric parameters may also evolve differently
n the basis of patient conditions.
onclusions. A strategy of empiric ICD programming for
T/VF detection and therapy is at least as effective as
atient-specific, physician-tailored programming, as mea-
ured by many patient outcome metrics. Simplified and
re-specified ICD programming is possible without an
ncrease in shock-related morbidity.
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nline version of this article.
